Gilead Sciences Inc.’s massive hepatitis C franchise is fading, the company warned Tuesday, projecting that sales this year could be just two-thirds of what investors had been expecting. Revenue from the company’s drugs for the viral infection will be $7.5 billion to $9 billion in 2017, Gilead said in a statement.
Category: Merck & Co.
Bristol-Myers Falls Further Behind Merck in Lung Cancer Race
Bristol-Myers Squibb Co. fell after the drugmaker said it wouldn’t seek accelerated approval for a combination of its drugs to treat first-line lung cancer.